inVentiv to buy i3 & Campbell Alliance

By Nick Taylor

- Last updated on GMT

Related tags: Middle east, Executive officer

inVentiv Health is to acquire i3 and Campbell Alliance and realign into three operating units: clinical, consulting and commercial.

Since being acquired by Thomas H Lee Partners in August inVentiv has launched takeovers of Star Terre Sante, i3 and Campbell Alliance. Completion of these acquisitions will lead to inVentiv realigning into three operating units, with the clinical segment taking the i3 brand name.

Operating under the i3 brand, the combined organisation will be one of the top-tier CROs (contract research organisations) in the world with locations across North America, Latin America, Europe, the Middle East, Asia and Asia Pacific​”, said inVentiv.

The clinical unit will consist of i3, which includes Research, Pharma, Resourcing and Statprobe businesses, and existing inVentiv segments, such as MedFocus, Clinical Solutions and Smith Hanley. Glenn Bilawsky will remain as CEO of i3.

Following completion of the i3 sale, which is valued at approximately $400m (€290m), Ingenix, the current owner, will align its commercialisation, safety, regulatory and late phase services under a newly-launched Life Sciences division.

Campbell Alliance

A day after news of the i3 deal inVentiv published details a definitive agreement to acquire Campbell Alliance, a biopharm management consultancy. Campbell Alliance will operate independently as the consulting unit of inVentiv.

The third segment, commercial, will consist of the remaining elements of the legacy inVentiv organisation, namely communications, selling solutions and accelerators and patient outcomes. Commercial will be the largest unit with approximately $900m in annual revenues.

inVentiv expects to close both deals in the first half of 2011 and has financed the takeovers through a combination of debt and equity.


Paul Meister, executive chairman of inVentiv, has been made CEO of the company. Meister is founder and CEO of Liberty Lane Partners, a private equity firm involved in the August 2010 takeover of inVentiv.

From 1991 to 2006 Meister was an executive officer at Fisher Scientific.

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more